Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

How I manage acute respiratory failure in patients with hematological malignancies

Elie Azoulay, Johan Maertens, Virginie Lemiale

Blood (2024) 143 (11): 971–982.

https://doi.org/10.1182/blood.2023021414

Published: 2024

Journal Articles

Low Disease Burden Pre-CAR-T Cell Therapy for Children and AYA with B-ALL Is Associated with an Impaired Outcome When Obtained through Intensification of the Bridging Therapy

Blood (2023) 142 (Supplement 1): 2134.

https://doi.org/10.1182/blood-2023-175045

Published: 2023

Journal Articles

Prognosis of Hyperviscosity Syndrome in Newly Diagnosed Multiple Myeloma in Modern-Era Therapy: A Real-Life Monocentric Study

Pierre-Edouard Debureaux, Stephanie Harel, Nathalie Parquet, Virginie Lemiale, Virginie Siguret, Laurie Goubeau, Florence Morin, Bruno Royer, Wendy Cuccuini, Dikelele Elessa, Floriane Theves, Anne Brignier, Elie Azoulay, Bertrand Arnulf, Alexis Talbot

Blood (2022) 140 (Supplement 1): 10046–10047.

https://doi.org/10.1182/blood-2022-156598

Published: 2022

Journal Articles

A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP

Blood (2021) 137 (6): 733–742.

https://doi.org/10.1182/blood.2020008021

Published: 2021

Includes: Supplemental data

Journal Articles

Convalescent plasma therapy for B-cell–depleted patients with protracted COVID-19

Blood (2020) 136 (20): 2290–2295.

https://doi.org/10.1182/blood.2020008423

Published: 2020

Includes: Supplemental data

Journal Articles

Immune thrombotic thrombocytopenic purpura in older patients: prognosis and long-term survival

Blood (2019) 134 (24): 2209–2217.

https://doi.org/10.1182/blood.2019000748

Published: 2019

Includes: Supplemental data

Journal Articles

CD19 CAR T-Cell Therapy in Patients with Relapse/Refractory DLBCL: Retrospective Analysis of the Eligibility Criteria

Blood (2019) 134 (Supplement_1): 2887.

https://doi.org/10.1182/blood-2019-129532

Published: 2019

Journal Articles

Safety and Efficacy of Tisagenlecleucel (CTL019) in B-Cell Acute Lymphoblastic Leukemia in Children, Adolescents and Young Adults: The French Experience

Blood (2019) 134 (Supplement_1): 3876.

https://doi.org/10.1182/blood-2019-131123

Published: 2019

Journal Articles

Thrombotic Thrombocytopenic Purpura Misdiagnosed As Autoimmune Cytopenia: Causes of Diagnostic Errors and Consequence on Outcome. Experience of the French Thrombotic Microangiopathies Reference Centre

Maximilien Grall, MD, Ygal Benhamou, MD, Elie Azoulay, MD PhD, Eric Mariotte, MD, Lionel Galicier, MD, Steven Grange, MD, Virginie Barbay, MD, Dominique Bordessoule, MD PhD, Agnes Veyradier, MD PhD, Paul Coppo, MD PhD

Blood (2016) 128 (22): 3730.

https://doi.org/10.1182/blood.V128.22.3730.3730

Published: 2016

Journal Articles

Neutropenic Enterocolitis: Clinical Features and Outcomes

Delphine Lebon, MD, Emmanuel Canet, MD, Lucie Biard, MD, David Schnell, MD, Camille Roussel, Sophie Buyse, Benoit Schlemmer, MD PhD, Elie Azoulay, MD PhD

Blood (2014) 124 (21): 5984.

https://doi.org/10.1182/blood.V124.21.5984.5984

Published: 2014

Journal Articles

Oral Hydroxyurea Before Intensive Chemotherapy For Hyperleucocytic Acute Myeloid Leukemia Patients

Anne-claire Mamez, MD, Emmanuel Raffoux, MD, Sylvie Chevret, MD, PhD, Virginie Lemiale, MD, Nicolas Boissel, MD, PhD, Emmanuel Canet, MD, Benoît Schlemmer, MD, PhD, Herve Dombret, MD, PhD, Elie Azoulay, MD, PhD, Etienne Lengliné, MD

Blood (2013) 122 (21): 2657.

https://doi.org/10.1182/blood.V122.21.2657.2657

Published: 2013

Journal Articles

Intensive Care Management and Outcomes In Allogeneic Hematopoietic Stem Cell Transplantation Recipients

Etienne Lengliné, MD, anne-Sophie Moreau, MD, Sylvie Chevret, MD, PhD, Frederic Pene, MD, PhD, François Blot, MD, Jean-Henri Bourhis, MD, Agnes Buzyn, MD, PhD, Benoît Schlemmer, MD, PhD, Gérard Socié, MD, PhD, Elie Azoulay, MD, PhD

Blood (2013) 122 (21): 4560.

https://doi.org/10.1182/blood.V122.21.4560.4560

Published: 2013

Journal Articles

Unexpected frequency of Upshaw-Schulman syndrome in pregnancy-onset thrombotic thrombocytopenic purpura

Marie Moatti-Cohen, Céline Garrec, Martine Wolf, Pierre Boisseau, Lionel Galicier, Elie Azoulay, Alain Stepanian, Yahsou Delmas, Eric Rondeau, Stéphane Bezieau, Paul Coppo, Agnès Veyradier

Blood (2012) 119 (24): 5888–5897.

https://doi.org/10.1182/blood-2012-02-408914

Published: 2012

Includes: Supplemental data

Journal Articles

Development and Validation of a Predictive Model for Death in Acquired Severe ADAMTS13 Deficiency-Associated Idiopathic Thrombotic Thrombocytopenic Purpura: The French TMA Reference Center Experience

Ygal Benhamou, Cyrielle Assie, Pierre-Yves Boelle, Marc Buffer, Rana Grillberger, PharmD, Sandrine Malot, Dominique Bordessoule, Lionel Galicier, MD, Elie Azoulay, MD, PhD, Hanspeter Rottensteiner, PhD, Agnes Veyradier, Paul Coppo

Blood (2011) 118 (21): 2229.

https://doi.org/10.1182/blood.V118.21.2229.2229

Published: 2011

Journal Articles

Early Admission to the Intensive Care Unit In High Risk Acute Myeloid Leukemia Patients

Etienne Lengliné, Emmanuel Raffoux, MD, Vincent Peigne, MD, Virginie Lemiale, MD, Mickael Darmon, MD, Nicolas Boissel, MD, PhD, Benoit Schlemmer, MD, Herve Dombret, MD, Elie Azoulay, MD, PhD

Blood (2010) 116 (21): 4364.

https://doi.org/10.1182/blood.V116.21.4364.4364

Published: 2010

Journal Articles

Do Early Events Excluding Patients with Acute Promyelocytic Leukemia (APL) From Trial Enrollment Modify Treatment Result Evaluation? Real-Life Management of 100 Patients Referred to the University Hospital Saint-Louis Between 2000 and 2010.

Jean-Baptiste Micol, Emmanuel Raffoux, MD, Nicolas Boissel, MD, PhD, Etienne Lengliné, MD, Emmanuel Canet, Thierry Leblanc, Marie-Thérèse Daniel, Adrienne de Labarthe, Odile Maarek, Bruno Cassinat, Christine Chomienne, MD, PhD, Lionel Adès, André Baruchel, Laurent Degos, Elie Azoulay, MD, PhD, Hervé Dombret

Blood (2010) 116 (21): 1083.

https://doi.org/10.1182/blood.V116.21.1083.1083

Published: 2010

Journal Articles

HLA-DRB1*11: a Strong Risk Factor for Acquired Severe ADAMTS13 Deficiency-Related Idiopathic Thrombotic Thrombocytopenic Purpura in Caucasians.

Paul Coppo, Virginia Lepage, Marc Busson, Agnes Veyradier, Karine Clabault, Alain Wynckel, Pascale Poullin, Sandrine Malot, Elie Azoulay, Lionel Galicier, Marc Buffet, Dominique Bordessoule, Jean-Paul Mira, Eric Rondeau, Dominique Charron, MD, PhD, Pascale Loiseau

Blood (2009) 114 (22): 2412.

https://doi.org/10.1182/blood.V114.22.2412.2412

Published: 2009

Journal Articles

First-Line Rituximab Efficacy and Safety in Patients with Acquired Idiopathic Thrombotic Thrombocytopenic Purpura Experiencing a Non Optimal Response to Therapeutical Plasma Exchange: Results of a Prospective Multicenter Phase 2 Study From the French Reference Center for the Management of Thrombotic Microangiopathies.

Blood (2009) 114 (22): 890.

https://doi.org/10.1182/blood.V114.22.890.890

Published: 2009

Journal Articles

Idiopathic Thrombotic Microangiopathies: Antinuclear Antibodies, Platelet Count and Creatinin Level Can Predict a Severe ADAMTS13 Deficiency.

Paul Coppo, MD, PhD, Alain Wynckel, MD, Karine Clabault, MD, Mickael Schwarzinger, MD, Matthieu Monge, MD, Pascale Poullin, MD, Elie Azoulay, MD, PhD, Lionel Galicier, MD, Jean-Paul Mira, MD, PhD, Dominique Bordessoule, MD, Norbert C. Gorin, MD, Jean-Paul Vernant, MD, Agnès Veyradier

Blood (2007) 110 (11): 3923.

https://doi.org/10.1182/blood.V110.11.3923.3923

Published: 2007

Journal Articles

Prognostic value of anti-ADAMTS13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS13 activity

Blood (2006) 109 (7): 2815–2822.

https://doi.org/10.1182/blood-2006-02-006064

Published: 2006

NARROW

How I manage acute respiratory failure in patients with hematological malignancies

Low Disease Burden Pre-CAR-T Cell Therapy for Children and AYA with B-ALL Is Associated with an Impaired Outcome When Obtained through Intensification of the Bridging Therapy

Prognosis of Hyperviscosity Syndrome in Newly Diagnosed Multiple Myeloma in Modern-Era Therapy: A Real-Life Monocentric Study

A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP

Convalescent plasma therapy for B-cell–depleted patients with protracted COVID-19

Immune thrombotic thrombocytopenic purpura in older patients: prognosis and long-term survival

CD19 CAR T-Cell Therapy in Patients with Relapse/Refractory DLBCL: Retrospective Analysis of the Eligibility Criteria

Safety and Efficacy of Tisagenlecleucel (CTL019) in B-Cell Acute Lymphoblastic Leukemia in Children, Adolescents and Young Adults: The French Experience

Thrombotic Thrombocytopenic Purpura Misdiagnosed As Autoimmune Cytopenia: Causes of Diagnostic Errors and Consequence on Outcome. Experience of the French Thrombotic Microangiopathies Reference Centre

Neutropenic Enterocolitis: Clinical Features and Outcomes

Oral Hydroxyurea Before Intensive Chemotherapy For Hyperleucocytic Acute Myeloid Leukemia Patients

Intensive Care Management and Outcomes In Allogeneic Hematopoietic Stem Cell Transplantation Recipients

Unexpected frequency of Upshaw-Schulman syndrome in pregnancy-onset thrombotic thrombocytopenic purpura

Development and Validation of a Predictive Model for Death in Acquired Severe ADAMTS13 Deficiency-Associated Idiopathic Thrombotic Thrombocytopenic Purpura: The French TMA Reference Center Experience

Early Admission to the Intensive Care Unit In High Risk Acute Myeloid Leukemia Patients

Do Early Events Excluding Patients with Acute Promyelocytic Leukemia (APL) From Trial Enrollment Modify Treatment Result Evaluation? Real-Life Management of 100 Patients Referred to the University Hospital Saint-Louis Between 2000 and 2010.

HLA-DRB1*11: a Strong Risk Factor for Acquired Severe ADAMTS13 Deficiency-Related Idiopathic Thrombotic Thrombocytopenic Purpura in Caucasians.

Idiopathic Thrombotic Microangiopathies: Antinuclear Antibodies, Platelet Count and Creatinin Level Can Predict a Severe ADAMTS13 Deficiency.

Prognostic value of anti-ADAMTS13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS13 activity

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only